Analyst picks & changes
| Company|| Bank|| Analyst|| Coverage|| Opinion|| Wk chg|| 3/9 cls|
| Anesiva (ANSV)|| Lazard|| Megan Murphy|| New|| Buy|| 1%|| $7.56|
| Murphy set a $10 target. She believes 4975, a non-narcotic injectable capsaicin anesthetic, will enter Phase III trials this year and is an asset with low clinical risk and significant market potential. She expects a 2008 partnership for moderate and severe osteoarthritis.|
| Aspreva (TSX:ASV; ASPV)|| Stanford Group|| Hanzhong Li|| New|| Buy|| -5%|| $20.99|
| Li set a $28 target. He believes ASV has a favorable risk/reward profile as CellCept's off-label autoimmune sales continue to grow ahead of Phase III data for lupus nephritis, which are expected in 2Q07.
Read the full 1097 word article